Use of lenacapavir in people with HIV who are heavily treatment-experienced resulted in high levels of virologic suppression, according to two small studies presented at the Infectious Disease Week (IDWeek) 2025 Annual Meeting.
In one study, 77% of participants were on a complex regimen of at least two core antiretroviral agents before starting lenacapavir, and over half (56%) saw their regimens simplify when they started or over the course of taking it. Most remained on the drug with high adherence to the injection schedule. In the other study, over half the participants were not virologically suppressed when they started lenacapavir, but the majority of those patients (82%) achieved and maintained suppression once starting.
Read the full news story here.
/Medscape requires free registration/
Source : Medscape
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.